NAD+ Injection: What the Human Evidence Actually Covers

NAD+ injections are the middle option between an IV drip in a clinic and a nasal spray at home. They are given subcutaneously, they take minutes rather than hours, and they are the format most people end up on when they want NAD+ without an appointment.

What follows is what is documented about injected NAD+, what is not, and where the regulatory position sits. The short version: the human evidence for injected NAD+ specifically is thinner than the market implies, and most of what gets cited in support of it comes from studies of a different molecule taken by a different route.

What NAD+ is

Nicotinamide adenine dinucleotide is a coenzyme present in every cell. It is a required cofactor in the reactions cells use to produce ATP, it participates in DNA repair through the PARP enzymes, and it is involved in sirtuin signalling. Tissue concentrations decline with age in several animal models and in some human tissue studies.

That decline is the reasoning behind the entire NAD+ market. The reasoning is sound as far as it goes. Whether raising NAD+ from an external source produces meaningful clinical benefit in healthy adults is a separate question the literature has not settled.

The evidence problem, stated plainly

There is a distinction that most pages on this topic collapse, and it matters:

• Oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have multiple placebo-controlled human trials. They consistently raise blood NAD+ metabolite levels. Downstream clinical outcomes have been inconsistent, with generally small or absent effects in healthy adults.
• NAD+ itself, injected, has very limited published human data.

These are different molecules taken by different routes. A trial showing that oral NR raises NAD+ metabolites is not evidence for what a subcutaneous NAD+ injection does. When a page cites the Martens 2018 nicotinamide riboside trial in support of an injection product, it is borrowing evidence that does not transfer.

Injection compared with the other routes

	Subcutaneous injection	IV infusion	Nasal spray
Published human absorption data	Limited	Limited	None
Where	At home	Clinic or infusion centre	At home
Session length	Minutes	One to four hours	Seconds
Needle	Small gauge	Cannula	None
Commonly reported effects	Injection site reactions	Flushing, nausea, chest tightness during infusion	Nasal irritation
Available through PrescribedRX	Yes	No	Yes

No published human study has compared absorption or outcomes across these routes, so this page does not rank them. The differences that can be documented are practical ones. Anyone presenting a bioavailability percentage by route for NAD+ is presenting a figure that does not come from a human study.

Where the regulatory position stands

• There is no FDA approved NAD+ drug product by any route. Compounded NAD+ is an unapproved drug.
• NAD+ appears in Category 1 of FDA’s 503A bulk drug substances evaluation, list updated 14 May 2026, and on the 503B nominations list. Category 1 is a nomination and an interim enforcement discretion posture while FDA completes its evaluation. It is not an approval and not an endorsement, and the phrase “FDA Category 1 approved” describes something that does not exist.
• In a warning letter to GenoGenix LLC dated 20 January 2026, FDA stated that the facility “compounded drug products using bulk drug substances that are not eligible for the use in compounding under section 503B, including 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and nicotinamide adenine dinucleotide (NAD+)” and that products compounded with those substances “are not eligible for the exemptions provided by section 503B.” That letter concerned a 503B outsourcing facility. Section 503A, compounding against an individual prescription, is a separate pathway with separate eligibility rules.
• Olympia Pharmacy issued a nationwide recall of compounded sterile preparations including NAD and sermorelin on 10 March 2022 for out-of-specification product. That was a manufacturing quality failure rather than a finding about the substance.

The pathway question is worth asking your provider directly: which compounding pathway is the NAD+ you are being prescribed made under, and which pharmacy is filling it. A provider who can answer that is worth more than one who cannot.

What injections involve in practice

Subcutaneous injection means into the fat layer beneath the skin rather than into muscle, using a short, small-gauge needle. It is the same technique used for many self-administered medications.

Technique, site rotation, storage and disposal should be demonstrated by the prescriber or pharmacist rather than learned from an article. Reported effects centre on injection site reactions: redness, tenderness or swelling where the injection was given. Some people report flushing or a warm sensation.

Because there is no approved label, there is no standardised adverse event document of the kind an approved drug carries. That is a limitation of the evidence, not a demonstration of safety.

Claims this page does not make

PrescribedRX dispenses NAD+ preparations, so it is worth being explicit about which common claims are deliberately absent:

• No bioavailability percentage for injected NAD+, because no published human pharmacokinetic study supports one.
• No ranking of injection against IV or nasal, because no comparative human study exists.
• No results timeline. No controlled trial establishes one.
• No use of oral NR or NMN trial results as evidence for injected NAD+.
• No description of NAD+ as FDA approved, FDA cleared or “Category 1 approved.”

Information a clinician will want

Because controlled human data is limited for every route, a prescriber will generally want a full history. Points that commonly matter include pregnancy or breastfeeding, a current or previous cancer diagnosis, significant kidney or liver impairment, and any medication with a narrow therapeutic window. NAD+ has not been studied in people with active cancer, which is a gap in the evidence rather than a finding in either direction.

Frequently asked

Is NAD+ injection FDA approved?

No. There is no FDA approved NAD+ drug product by any route.

Is injection better than IV?

No published human study has compared them, so the comparison cannot be made from evidence. The documented differences are practical: setting, session length and time required.

How much is absorbed from a subcutaneous injection?

Published human pharmacokinetic data for injected NAD+ is very limited, and this page does not publish a figure that the literature does not support.

Do the oral NAD+ studies apply?

Not directly. Those trials studied nicotinamide riboside or nicotinamide mononucleotide taken orally, which is a different molecule by a different route.

References

1. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286.
2. U.S. Food and Drug Administration. Warning Letter to GenoGenix LLC, 20 January 2026.
3. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated 14 May 2026.
4. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Updated 21 March 2025.
5. U.S. Food and Drug Administration. Olympia Pharmacy issues voluntary nationwide recall of compounded sterile preparations, 10 March 2022.
6. Ying W, Wei G, Wang D, et al. Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Frontiers in Bioscience. 2007;12:2728–2734. PubMed ID 17127275.

Related reading

NAD+ therapy: the complete guide · NAD+ IV vs injection vs nasal spray · NAD+ nasal spray: what the evidence shows · Longevity treatments